CYP3A4 and tuberculosis: Rifampin-based tuberculosis treatment was found to decrease lumefantrine exposure by 59%, which was expected, since rifampin is known to be a potent inducer of CYP3A4, and previous physiologically based pharmacokinetic modeling had predicted this in silico (28).